Pseudomonas aeruginosa Infections – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Pseudomonas aeruginosa Infections – Pipeline Review, H2 2016’, provides an overview of the Pseudomonas aeruginosa Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pseudomonas aeruginosa Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pseudomonas aeruginosa Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Pseudomonas aeruginosa Infections

The report reviews pipeline therapeutics for Pseudomonas aeruginosa Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Pseudomonas aeruginosa Infections therapeutics and enlists all their major and minor projects

The report assesses Pseudomonas aeruginosa Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Pseudomonas aeruginosa Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Pseudomonas aeruginosa Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Pseudomonas aeruginosa Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achaogen Inc

Adenium Biotech ApS

Aeolus Pharmaceuticals Inc

AlgiPharma AS

AmpliPhi Biosciences Corp

AnGes MG Inc

Arch Biopartners, Inc.

Aridis Pharmaceuticals LLC

Arno Therapeutics Inc

AstraZeneca Plc

Biolytics Pharma

Catabasis Pharmaceuticals Inc

Cellceutix Corp

CSA Biotechnologies LLC

Cyclacel Pharmaceuticals Inc

Evaxion Biotech ApS

F. Hoffmann-La Roche Ltd

FOB Synthesis Inc

GlaxoSmithKline Plc

Helix BioMedix Inc

Hsiri Therapeutics LLC

Immun System IMS AB

Insmed Inc

Lascco SA

Laurent Pharmaceuticals Inc

LegoChem Biosciences Inc

Lytix Biopharma AS

MedImmune LLC

Melinta Therapeutics Inc

Microbiotix Inc

Nosopharm SAS

Novabiotics Ltd

Omnia Molecular Ltd

Peptilogics Inc

Pfizer Inc

Pherecydes Pharma SA

Phico Therapeutics Ltd

Polyphor Ltd

Procarta Biosystems Ltd

Sanofi

Sarepta Therapeutics Inc

Sealife PHARMA GMBH

Sequoia Sciences Inc

Shionogi & Co Ltd

Soligenix Inc

Syntiron LLC

Tetraphase Pharmaceuticals Inc

Varinel Inc

Vaxdyn SL

Zambon Company SpA

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Pseudomonas aeruginosa Infections Overview 6

Therapeutics Development 7

Pseudomonas aeruginosa Infections - Therapeutics under Development by Companies 9

Pseudomonas aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes 13

Pseudomonas aeruginosa Infections - Pipeline Products Glance 15

Pseudomonas aeruginosa Infections - Products under Development by Companies 19

Pseudomonas aeruginosa Infections - Products under Investigation by Universities/Institutes 24

Pseudomonas aeruginosa Infections - Companies Involved in Therapeutics Development 26

Pseudomonas aeruginosa Infections - Therapeutics Assessment 76

Drug Profiles 88

Pseudomonas aeruginosa Infections - Dormant Projects 220

Pseudomonas aeruginosa Infections - Discontinued Products 225

Pseudomonas aeruginosa Infections - Product Development Milestones 226

Appendix 237

List of Tables

List of Tables

Number of Products under Development for Pseudomonas aeruginosa Infections, H2 2016 19

Number of Products under Development for Pseudomonas aeruginosa Infections – Comparative Analysis, H2 2016 20

Number of Products under Development by Companies, H2 2016 21

Number of Products under Development by Companies, H2 2016 (Contd..1) 22

Number of Products under Development by Companies, H2 2016 (Contd..2) 23

Number of Products under Development by Companies, H2 2016 (Contd..3) 24

Number of Products under Investigation by Universities/Institutes, H2 2016 26

Comparative Analysis by Late Stage Development, H2 2016 27

Comparative Analysis by Clinical Stage Development, H2 2016 28

Comparative Analysis by Early Stage Development, H2 2016 29

Comparative Analysis by Unknown Stage Development, H2 2016 30

Products under Development by Companies, H2 2016 31

Products under Development by Companies, H2 2016 (Contd..1) 32

Products under Development by Companies, H2 2016 (Contd..2) 33

Products under Development by Companies, H2 2016 (Contd..3) 34

Products under Development by Companies, H2 2016 (Contd..4) 35

Products under Investigation by Universities/Institutes, H2 2016 36

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 37

Pseudomonas aeruginosa Infections – Pipeline by Achaogen Inc, H2 2016 38

Pseudomonas aeruginosa Infections – Pipeline by Adenium Biotech ApS, H2 2016 39

Pseudomonas aeruginosa Infections – Pipeline by Aeolus Pharmaceuticals Inc, H2 2016 40

Pseudomonas aeruginosa Infections – Pipeline by AlgiPharma AS, H2 2016 41

Pseudomonas aeruginosa Infections – Pipeline by AmpliPhi Biosciences Corp, H2 2016 42

Pseudomonas aeruginosa Infections – Pipeline by AnGes MG Inc, H2 2016 43

Pseudomonas aeruginosa Infections – Pipeline by Arch Biopartners, Inc., H2 2016 44

Pseudomonas aeruginosa Infections – Pipeline by Aridis Pharmaceuticals LLC, H2 2016 45

Pseudomonas aeruginosa Infections – Pipeline by Arno Therapeutics Inc, H2 2016 46

Pseudomonas aeruginosa Infections – Pipeline by AstraZeneca Plc, H2 2016 47

Pseudomonas aeruginosa Infections – Pipeline by Biolytics Pharma, H2 2016 48

Pseudomonas aeruginosa Infections – Pipeline by Catabasis Pharmaceuticals Inc, H2 2016 49

Pseudomonas aeruginosa Infections – Pipeline by Cellceutix Corp, H2 2016 50

Pseudomonas aeruginosa Infections – Pipeline by CSA Biotechnologies LLC, H2 2016 51

Pseudomonas aeruginosa Infections – Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 52

Pseudomonas aeruginosa Infections – Pipeline by Evaxion Biotech ApS, H2 2016 53

Pseudomonas aeruginosa Infections – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 54

Pseudomonas aeruginosa Infections – Pipeline by FOB Synthesis Inc, H2 2016 55

Pseudomonas aeruginosa Infections – Pipeline by GlaxoSmithKline Plc, H2 2016 56

Pseudomonas aeruginosa Infections – Pipeline by Helix BioMedix Inc, H2 2016 57

Pseudomonas aeruginosa Infections – Pipeline by Hsiri Therapeutics LLC, H2 2016 58

Pseudomonas aeruginosa Infections – Pipeline by Immun System IMS AB, H2 2016 59

Pseudomonas aeruginosa Infections – Pipeline by Insmed Inc, H2 2016 60

Pseudomonas aeruginosa Infections – Pipeline by Lascco SA, H2 2016 61

Pseudomonas aeruginosa Infections – Pipeline by Laurent Pharmaceuticals Inc, H2 2016 62

Pseudomonas aeruginosa Infections – Pipeline by LegoChem Biosciences Inc, H2 2016 63

Pseudomonas aeruginosa Infections – Pipeline by Lytix Biopharma AS, H2 2016 64

Pseudomonas aeruginosa Infections – Pipeline by MedImmune LLC, H2 2016 65

Pseudomonas aeruginosa Infections – Pipeline by Melinta Therapeutics Inc, H2 2016 66

Pseudomonas aeruginosa Infections – Pipeline by Microbiotix Inc, H2 2016 67

Pseudomonas aeruginosa Infections – Pipeline by Nosopharm SAS, H2 2016 68

Pseudomonas aeruginosa Infections – Pipeline by Novabiotics Ltd, H2 2016 69

Pseudomonas aeruginosa Infections – Pipeline by Omnia Molecular Ltd, H2 2016 70

Pseudomonas aeruginosa Infections – Pipeline by Peptilogics Inc, H2 2016 71

Pseudomonas aeruginosa Infections – Pipeline by Pfizer Inc, H2 2016 72

Pseudomonas aeruginosa Infections – Pipeline by Pherecydes Pharma SA, H2 2016 73

Pseudomonas aeruginosa Infections – Pipeline by Phico Therapeutics Ltd, H2 2016 74

Pseudomonas aeruginosa Infections – Pipeline by Polyphor Ltd, H2 2016 75

Pseudomonas aeruginosa Infections – Pipeline by Procarta Biosystems Ltd, H2 2016 76

Pseudomonas aeruginosa Infections – Pipeline by Sanofi, H2 2016 77

Pseudomonas aeruginosa Infections – Pipeline by Sarepta Therapeutics Inc, H2 2016 78

Pseudomonas aeruginosa Infections – Pipeline by Sealife PHARMA GMBH, H2 2016 79

Pseudomonas aeruginosa Infections – Pipeline by Sequoia Sciences Inc, H2 2016 80

Pseudomonas aeruginosa Infections – Pipeline by Shionogi & Co Ltd, H2 2016 81

Pseudomonas aeruginosa Infections – Pipeline by Soligenix Inc, H2 2016 82

Pseudomonas aeruginosa Infections – Pipeline by Syntiron LLC, H2 2016 83

Pseudomonas aeruginosa Infections – Pipeline by Tetraphase Pharmaceuticals Inc, H2 2016 84

Pseudomonas aeruginosa Infections – Pipeline by Varinel Inc, H2 2016 85

Pseudomonas aeruginosa Infections – Pipeline by Vaxdyn SL, H2 2016 86

Pseudomonas aeruginosa Infections – Pipeline by Zambon Company SpA, H2 2016 87

Assessment by Monotherapy Products, H2 2016 88

Assessment by Combination Products, H2 2016 89

Number of Products by Stage and Target, H2 2016 91

Number of Products by Stage and Mechanism of Action, H2 2016 94

Number of Products by Stage and Route of Administration, H2 2016 97

Number of Products by Stage and Molecule Type, H2 2016 99

Pseudomonas aeruginosa Infections – Dormant Projects, H2 2016 232

Pseudomonas aeruginosa Infections – Dormant Projects (Contd..1), H2 2016 233

Pseudomonas aeruginosa Infections – Dormant Projects (Contd..2), H2 2016 234

Pseudomonas aeruginosa Infections – Dormant Projects (Contd..3), H2 2016 235

Pseudomonas aeruginosa Infections – Dormant Projects (Contd..4), H2 2016 236

Pseudomonas aeruginosa Infections – Discontinued Products, H2 2016 237

List of Figures

List of Figures

Number of Products under Development for Pseudomonas aeruginosa Infections, H2 2016 19

Number of Products under Development for Pseudomonas aeruginosa Infections – Comparative Analysis, H2 2016 20

Number of Products under Development by Companies, H2 2016 21

Number of Products under Investigation by Universities/Institutes, H2 2016 25

Comparative Analysis by Late Stage Development, H2 2016 27

Comparative Analysis by Clinical Stage Development, H2 2016 28

Comparative Analysis by Early Stage Products, H2 2016 29

Comparative Analysis by Unknown Stage Development, H2 2016 30

Assessment by Monotherapy Products, H2 2016 88

Assessment by Combination Products, H2 2016 89

Number of Products by Top 10 Targets, H2 2016 90

Number of Products by Stage and Top 10 Targets, H2 2016 90

Number of Products by Top 10 Mechanism of Actions, H2 2016 93

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 93

Number of Products by Routes of Administration, H2 2016 96

Number of Products by Stage and Routes of Administration, H2 2016 96

Number of Products by Top 10 Molecule Types, H2 2016 98

Number of Products by Stage and Top 10 Molecule Types, H2 2016 98

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports